ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Summary

This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.

Eligibility

Inclusion Criteria:

1. Willing and able to provide signed and dated informed consent;
2. Patients at least 18 years of age;
3. Locally advanced or metastatic non-small cell lung cancer (NSCLC);
4. Objective disease progression following prior EGFR-TKI therapy;
5. EGFR mutation with MET amplification/Overexpression by a central laboratory;
6. Measurable lesions based on RECIST 1. 1;
7. ECOG performance status 0 or 1;
8. Expected survival \>12 weeks;
9. Adequate bone marrow reserve or organ function.

Exclusion Criteria:

1. Prior or ongoing treatment with any c-Met target;
2. Previously received systemic chemotherapy;
3. Patients requiring continuous use of systemic immunosuppressants or systemic corticosteroids within 2 weeks prior to the first dose.
4. Patients who underwent other major surgical procedures other than diagnosis or biopsy within 4 weeks prior to the first dose, or who were expected to undergo major surgeries during the study period;
5. Prior to the first administration, there are unhealed toxic reactions of ≥ grade 2 (CTCAE 5.0 standard) associated with any previous treatment, any level of hair loss, and platinum drugs Except for grade 2 neuropathy caused;
6. Patients with leptomeningeal metastasis, brainstem metastasis, or spinal cord compression;
7. Presence of dysphagia or gastrointestinal disorders that may interfere with oral medication absorption;
8. Previous history includes interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis requiring steroid therapy, or evidence of clinically active ILD；
9. Have previously received hematopoietic stem cell transplants or solid organ transplants, or plan to receive hematopoietic stem cell transplants or solid organ transplants during the current period of study;
10. There are serious or active infections that required intravenous antibiotics or hospitalization, such as HBV (HBsAg-positive and peripheral HBV-DNA titer test≥1×104 copies/mL or 2000 IU/mL), HCV, HIV, and syphilis;
11. Serious or uncontrolled cardiovascular disease;
12. Pregnant or lactating females;
13. Other primary malignancies have been diagnosed within the last 5 years, and the following conditions can be enrolled: non-melanoma skin cancer, superficial bladder cancer, cervical carcinoma in situ that has undergone surgery and has been cured;

Conditions3

Interventions2

Related trials

• A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. — Eikon Therapeutics
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations — Alterome Therapeutics, Inc.
• Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC — Revolution Medicines, Inc.

Browse More Trials